Latest Media Releases (Page 4) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - A$100 million fully underwritten equity raising (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or Company) is pleased to announce that it has launched a fully underwritten approximately $100 million equity raising (Offer) through a pro rata ...read more

INOVIQ - Breakthrough Exosome Therapy (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has successfully produced and isolated engineered exosomes (EEVs) that target and kill breast cancer cells in vitro. In a proof-o...read more

Immutep - AIPAC-003 safety lead-in data presented at ESMO Breast 2024 (ASX:IMM)

Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel ...read more

Immutep - Positive initial data in phase 2 Soft Tissue Sarcoma trial (ASX:IMM)

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four ...read more

INOVIQ - Quarterly Activities Report and Appendix 4C - March 2024 (ASX:IIQ)

In lodging the quarterly business update, new Chairman David Williams said “IIQ has a unique offering that is partly de-risked by having its technology launched in the market. Better still, st...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patie...read more

Immutep - Positive preliminary topline results from TACTI-003 Cohort B (ASX:IMM)

Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9%...read more

INOVIQ - Ovarian Cancer Test Validation (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce the successful completion of an analytical validation study for its blood test for ovarian cancer. Overall, the test correctly identified 85...read more

Immutep - CHDR to conduct first-in-human phase 1 trial of IMP761 (ASX:IMM)

-- Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the under...read more

INOVIQ Investor Update (ASX:IIQ)

To view the presentation, download the attached PDF.

Immutep - Positive Feedback received from Spanish Medicines Agency (ASX:IMM)

SYDNEY, AUSTRALIA – April 17, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...read more

INOVIQ and Promega sign Global EXO-NET Agreement (ASX:IIQ)

INOVIQ Ltd (ASX:IIQ) (INOVIQ) and Promega Corporation (Promega) are partnering to unlock the commercial potential of exosomes for research, diagnostic and therapeutic applications. This agreement wi...read more

Chimeric Therapeutics - Clinical milestones for 2024 & 2023 successes highlighted (ASX:CHM)

-- Reported positive preliminary data for CHM 1101 in heavily pretreated glioblastoma patients, confirming advancement to next phase of CHM 1101 development -- FDA IND clearance for CHM 2101 enabli...read more

Immutep - First Clinical Data announced from 90mg Dosing of Efti (ASX:IMM)

-- Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated -- Encouraging initial efficacy in six metastatic breast cancer pati...read more

Paragon Care - PGC-CH2 Merger Further Information (ASX:PGC)

ParagonCare refers to the proposed merger with CH2 by way of the acquisition of all of the issued share capital in CH2 from the relevant sellers in exchange for issuing approximately 943,524,071 sha...read more

Viewing: 46 - 60 of 200 Previous | Next